文献速递贫血与红细胞疾病

转铁蛋白受体2是β-地中海贫血的潜在新治疗靶点:来自小鼠模型的证据

Transferrin receptor 2 is a potential novel therapeutic target for β-thalassemia: evidence from a murine model.
PubMed 文献 · Blood · 2018-09-12

研究在中间型地中海贫血小鼠模型中特异性敲除骨髓转铁蛋白受体2(Tfr2),发现红系细胞对促红细胞生成素更敏感,贫血与铁过载部分改善,但获益随时间减弱,可能与铁供应不足有关;Tfr2种系缺失(含单倍剂量不足)有类似效果。

要点

  • 骨髓Tfr2缺失使中间型地贫小鼠红系生成和红细胞形态改善,贫血与铁过载部分纠正。
  • 上述获益随时间减弱,可能与铁供应不足以维持增强的红系生成有关。
  • Tfr2种系缺失(包括单倍剂量不足)在地贫模型中产生类似效应。

核心结论

  • 靶向TFR2可增强EPO介导的效应,且仅作用于同时表达两种受体的细胞,可能优于红系生成刺激剂用于其他贫血的治疗。

研究设计与样本

  • 研究构建了中间型地中海贫血小鼠模型,并特异性缺失骨髓Tfr2,同时评估了Tfr2种系缺失(含单倍剂量不足)的效果。

主要发现

  • 骨髓Tfr2缺失的地贫小鼠红系细胞对EPO刺激更敏感,红系生成和红细胞形态改善,贫血与铁过载部分纠正。
  • 上述有益效应随时间减弱,可能与铁供应不足以维持增强的红系生成有关。
  • Tfr2种系缺失(包括单倍剂量不足)在地贫模型中产生类似效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

β-thalassemias are genetic disorders characterized by anemia, ineffective erythropoiesis, and iron overload. Current treatment of severe cases is based on blood transfusion and iron chelation or allogeneic bone marrow (BM) transplantation. Novel approaches are explored for nontransfusion-dependent patients (thalassemia intermedia) who develop anemia and iron overload. Here, we investigated the erythropoietin (EPO) receptor partner, transferrin receptor 2 (TFR2), as a novel potential therapeutic target. We generated a murine model of thalassemia intermedia specifically lacking BM Tfr2: because their erythroid cells are more susceptible to EPO stimulation, mice show improved erythropoiesis and red blood cell morphology as well as partial correction of anemia and iron overload. The beneficial effects become attenuated over time, possibly due to insufficient iron availability to sustain the enhanced erythropoiesis. Germ line deletion of Tfr2, including haploinsufficiency, had a similar effect in the thalassemic model. Because targeting TFR2 enhances EPO-mediated effects exclusively in cells expressing both receptors, this approach may have advantages over erythropoiesis-stimulating agents in the treatment of other anemias.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Artuso I, Lidonnici MR, Altamura S, et al. Transferrin receptor 2 is a potential novel therapeutic target for β-thalassemia: evidence from a murine model. Blood. 2018. PMID: 30209118. doi:10.1182/blood-2018-05-852277

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。